Showing 7,281 - 7,300 results of 18,297 for search 'significant ((((((gap decrease) OR (a decrease))) OR (nn decrease))) OR (mean decrease))', query time: 0.66s Refine Results
  1. 7281

    Factors associated with mosquito net integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  2. 7282

    LLINs knockdown performance over time. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  3. 7283

    Factors affecting PBO-LLINs integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  4. 7284

    Net bioefficacy data. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  5. 7285

    House structure and status. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  6. 7286

    LLINs hole positions over time. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  7. 7287
  8. 7288

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  9. 7289

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  10. 7290

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  11. 7291

    Table 3_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

    Published 2025
    “…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”
  12. 7292

    Table 1_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

    Published 2025
    “…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”
  13. 7293

    Table 2_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

    Published 2025
    “…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”
  14. 7294

    Infrared thermal images of typical subjects. by Yongliang Jiang (6200549)

    Published 2025
    “…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO<sub>2</sub> of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”
  15. 7295

    The CONSORT flowchart of the study. by Yongliang Jiang (6200549)

    Published 2025
    “…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO<sub>2</sub> of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”
  16. 7296

    Location of 4 somatic measurement sites. by Yongliang Jiang (6200549)

    Published 2025
    “…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO<sub>2</sub> of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”
  17. 7297

    Minimal data set. by Yongliang Jiang (6200549)

    Published 2025
    “…Regarding the thermal characteristics, compared with the healthy control group, the temperature of the somatic sites of the heart meridian (Shenmen(HT7)/Shaohai(HT3)), as well as Taiyuan (LU9) of the lung meridian, increased significantly (<i><i>P</i></i> < 0.05). With regard to the metabolic features, rSO<sub>2</sub> of the somatic site of the heart meridian (Shaohai (HT3)) in the CSAP group decreased significantly (<i><i>P</i></i> < 0.05) as compared to the healthy control group. …”
  18. 7298

    Changes in intraocular pressure (IOP) from before to after omidenepag isopropyl administration in different patient groups. by Kana Tokumo (21702784)

    Published 2025
    “…<b>(b)</b> Comparison of IOP before and after omidenepag isopropyl in the new administration group. There was a significant decrease in IOP after starting the eye drops (<i>P</i> = 0.03, Wilcoxon signed-rank test).…”
  19. 7299

    Data Sheet 1_Platelet count and retinopathy of prematurity, a systematic review and meta-analysis.docx by Qian Zeng (2866592)

    Published 2025
    “…The pooled analysis indicated a significant decrease in mean platelet count among the ROP group compared to the non-ROP group (mean difference: −18.65, 95% confidence interval: −22.80 to −14.50, P < .00001). …”
  20. 7300

    A, B. Effects on explicit instruction about prospects of alternative goals on behavior. by Sneha Aenugu (21364349)

    Published 2025
    “…<p><b>A.</b> Task performance improves with instructions yet significantly falls short of the optimal prospective agent. …”